Table of Contents
Hepatitis Research and Treatment
Volume 2016 (2016), Article ID 9671031, 11 pages
http://dx.doi.org/10.1155/2016/9671031
Research Article

Combinations of siRNAs against La Autoantigen with NS5B or hVAP-A Have Additive Effect on Inhibition of HCV Replication

1Centre for Advance Studies, Department of Botany, University of Calcutta, 35 Ballygunge Circular Road, Kolkata 700019, India
2Laboratory of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, UG and MUG, Abrahama 58 Street, 80-307 Gdańsk, Poland

Received 28 March 2016; Revised 23 May 2016; Accepted 30 May 2016

Academic Editor: Piero Luigi Almasio

Copyright © 2016 Anirban Mandal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Kanda, O. Yokosuka, and M. Omata, “Hepatitis C virus and hepatocellular carcinoma,” Biology, vol. 2, no. 1, pp. 304–316, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. World Health Organization, “Hepatitis C,” Fact Sheet Number 164, World Health Organization, Geneva, Switzerland, 2015, http://www.who.int/mediacentre/factsheets/fs164/en/. View at Google Scholar
  3. World Health Organization, Hepatitis C, World Health Organization, Geneva, Switzerland, 2003, http://www.who.int/csr/disease/hepatitis/Hepc.pdf.
  4. J. J. Feld and J. H. Hoofnagle, “Mechanism of action of interferon and ribavirin in treatment of hepatitis C,” Nature, vol. 436, no. 7053, pp. 967–972, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. R. T. Chung, M. Gale Jr., S. J. Polyak, S. M. Lemon, T. J. Liang, and J. H. Hoofnagle, “Mechanisms of action of interferon and ribavirin in chronic hepatitis C: summary of a workshop,” Hepatology, vol. 47, no. 1, pp. 306–320, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. K. J. Wilby, N. Partovi, J.-A. E. Ford, E. D. Greanya, and E. M. Yoshida, “Review of boceprevir and telaprevir for the treatment of chronic hepatitis C,” Canadian Journal of Gastroenterology, vol. 26, no. 4, pp. 205–210, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. A. Butt and F. Kanwal, “Boceprevir and telaprevir in the management of hepatitis C virus-infected patients,” Clinical Infectious Diseases, vol. 54, no. 1, pp. 96–104, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. HIVandHepatitis.com, “Vertex to Discontinue Sale of Telaprevir (Incivek) for Hepatitis C,” San Francisco, Cailf, USA, 2014, http://www.hivandhepatitis.com/hcv-treatment/approved-hcv-drugs/4808-vertex-to-discontinue-sale-of-telaprevir-incivek-for-hepatitis-c.
  9. HIVandHepatitis.com, Merck Plans to Discontinue Boceprevir for Hepatitis C by December 2015, HIVandHepatitis.com, San Francisco, Calif, USA, 2015, http://www.hivandhepatitis.com/hcv-treatment/approved-hcv-drugs/5021-merck-plans-to-discontinue-boceprevir-for-hepatitis-c-by-december-2015.
  10. N. Afdhal, K. R. Reddy, D. R. Nelson et al., “Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection,” The New England Journal of Medicine, vol. 370, no. 16, pp. 1483–1493, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. M. P. Manns, J. M. Vierling, B. R. Bacon et al., “The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis c virus genotype 1 infection without cirrhosis,” Gastroenterology, vol. 147, no. 2, pp. 366–376.e6, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Diana and H. Gregory, “Ledipasvir/sofosbuvir (Harvoni): improving options for hepatitis C virus infection,” P & T, vol. 40, no. 4, pp. 256–276, 2015. View at Google Scholar · View at Scopus
  13. FDA News Release, “FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4,” U.S. Food and Drug Administration, Silver Spring, Md, USA, 2016, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm483828.htm.
  14. A. Reynolds, D. Leake, Q. Boese, S. Scaringe, W. S. Marshall, and A. Khvorova, “Rational siRNA design for RNA interference,” Nature Biotechnology, vol. 22, no. 3, pp. 326–330, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. G. J. Hannon, “RNA interference,” Nature, vol. 418, no. 6894, pp. 244–251, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Motavaf, S. Safari, and S. M. Alavian, “Therapeutic potential of RNA interference: a new molecular approach to antiviral treatment for hepatitis C,” Journal of Viral Hepatitis, vol. 19, no. 11, pp. 757–765, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. J. A. Wilson, S. Jayasena, A. Khvorova et al., “RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 5, pp. 2783–2788, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. J.-S. Moon, S.-H. Lee, E.-J. Kim et al., “Inhibition of hepatitis C virus in mice by a small interfering RNA targeting a highly conserved sequence in viral IRES pseudoknot,” PLoS ONE, vol. 11, no. 1, Article ID e0146710, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Kanda, R. Steele, R. Ray, and R. B. Ray, “Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect,” Journal of Virology, vol. 81, no. 2, pp. 669–676, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Khaliq, S. Jahan, B. Ijaz, W. Ahmad, S. Asad, and S. Hassan, “Inhibition of hepatitis C virus genotype 3a by siRNAs targeting envelope genes,” Archives of Virology, vol. 156, no. 3, pp. 433–442, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Ding, Y. Liu, Z.-Q. Bian et al., “Stably silencing of CD81 expression by small interfering RNAs targeting 3′-NTR inhibits HCV infection,” Hepatitis Monthly, vol. 8, no. 4, pp. 267–274, 2008. View at Google Scholar · View at Scopus
  22. G. Randall, M. Panis, J. D. Cooper et al., “Cellular cofactors affecting hepatitis C virus infection and replication,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 31, pp. 12884–12889, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Jahan, B. Samreen, S. Khaliq et al., “HCV entry receptors as potential targets for siRNA-based inhibition of HCV,” Genetic Vaccines and Therapy, vol. 9, article 15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Randall, A. Grakoui, and C. M. Rice, “Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 1, pp. 235–240, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Takigawa, M. Nagano-Fujii, L. Deng et al., “Suppression of hepatitis C virus replicon by RNA interference directed against the NS3 and NS5B regions of the viral genome,” Microbiology and Immunology, vol. 48, no. 8, pp. 591–598, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Harris, Z. Zhang, B. Chaubey, and V. N. Pandey, “Identification of cellular factors associated with the 3′-nontranslated region of the hepatitis C virus genome,” Molecular and Cellular Proteomics, vol. 5, no. 6, pp. 1006–1018, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. D. M. Jones, P. Domingues, P. Targett-Adams, and J. McLauchlan, “Comparison of U2OS and Huh-7 cells for identifying host factors that affect hepatitis C virus RNA replication,” Journal of General Virology, vol. 91, no. 9, pp. 2238–2248, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. T. I. Ng, H. Mo, T. Pilot-Matias et al., “Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology,” Hepatology, vol. 45, no. 6, pp. 1413–1421, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. A. W. Tai, Y. Benita, L. F. Peng et al., “A functional genomic screen identifies cellular cofactors of hepatitis C virus replication,” Cell Host & Microbe, vol. 5, no. 3, pp. 298–307, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Konishi, C. H. Wu, M. Kaito et al., “siRNA-resistance in treated HCV replicon cells is correlated with the development of specific HCV mutations,” Journal of Viral Hepatitis, vol. 13, no. 11, pp. 756–761, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. J. A. Wilson and C. D. Richardson, “Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region,” Journal of Virology, vol. 79, no. 11, pp. 7050–7058, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Jahan, S. Khaliq, B. Samreen et al., “Effect of combined siRNA of HCV E2 gene and HCV receptors against HCV,” Virology Journal, vol. 8, article 295, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Jahan, B. Samreen, S. Khaliq et al., “HCV entry receptors as potential targets for siRNA-based inhibition of HCV,” Genetic Vaccines and Therapy, vol. 9, no. 1, article 15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. P. K. Chandra, A. K. Kundu, S. Hazari et al., “Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes,” Molecular Therapy, vol. 20, no. 9, pp. 1724–1736, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. D. A. Suhy, S.-C. Kao, T. Mao et al., “Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model,” Molecular Therapy, vol. 20, no. 9, pp. 1737–1749, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Korf, D. Jarczak, C. Beger, M. P. Manns, and M. Krüger, “Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors,” Journal of Hepatology, vol. 43, no. 2, pp. 225–234, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. A. M. Domitrovich, K. W. Diebel, N. Ali, S. Sarker, and A. Siddiqui, “Role of La autoantigen and polypyrimidine tract-binding protein in HCV replication,” Virology, vol. 335, no. 1, pp. 72–86, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Ali and A. Siddiqui, “The La antigen binds 5′ noncoding region of the hepatitis c virus RNA in the context of the initiator AUG codon and stimulates internal ribosome entry site-mediated translation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 6, pp. 2249–2254, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Spångberg, L. Wiklund, and S. Schwartz, “Binding of the La autoantigen to the hepatitis C virus 3′ untranslated region protects the RNA from rapid degradation in vitro,” Journal of General Virology, vol. 82, no. 1, pp. 113–120, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Krüger, C. Beger, P. J. Welch, J. R. Barber, M. P. Manns, and F. Wong-Staal, “Involvement of proteasome α-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation,” Molecular and Cellular Biology, vol. 21, no. 24, pp. 8357–8364, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Gao, H. Aizaki, J.-W. He, and M. M. C. Lai, “Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft,” Journal of Virology, vol. 78, no. 7, pp. 3480–3488, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Metz, A. Reuter, S. Bender, and R. Bartenschlager, “Interferon-stimulated genes and their role in controlling hepatitis C virus,” Journal of Hepatology, vol. 59, no. 6, pp. 1331–1341, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Amini-Bavil-Olyaee, Y. J. Choi, J. H. Lee et al., “The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry,” Cell Host and Microbe, vol. 13, no. 4, pp. 452–464, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. W. Zhong, A. S. Uss, E. Ferrari, J. Y. N. Lau, and Z. Hong, “De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase,” Journal of Virology, vol. 74, no. 4, pp. 2017–2022, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. V. Lohmann, A. Roos, F. Körner, J. O. Koch, and R. Bartenschlager, “Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus,” Journal of Viral Hepatitis, vol. 7, no. 3, pp. 167–174, 2000. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Gallagher, S. E. Winston, S. A. Fuller, and J. G. R. Hurrell, “Immunoblotting and immunodetection,” in Current Protocols in Molecular Biology, F. M. Ausubel, Ed., chapter 10, unit 10.8, pp. 10.8.1–10.8.28, John Wiley & Sons, New York, NY, USA, 2008. View at Google Scholar
  47. J. G. Donaldson, “Immunofluorescence staining,” in Current Protocols in Cell Biology, K. S. Morgan, Ed., chapter 4, unit 4.3, pp. 4.3.1–4.3.6, John Wiley & Sons, New York, NY, USA, 1998. View at Google Scholar
  48. T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55–63, 1983. View at Publisher · View at Google Scholar · View at Scopus
  49. T. Shirasaki, M. Honda, H. Mizuno et al., “La protein required for internal ribosome entry site-directed translation is a potential therapiutic target for hepaatitis C virus replication,” The Journal of Infectious Diseases, vol. 202, no. 1, pp. 75–85, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. M. L. Weir, A. Klip, and W. S. Trimble, “Identification of a human homologue of the vesicle-associated membrane protein (VAMP)-associated protein of 33 kDa (VAP-33): a broadly expressed protein that binds to VAMP,” Biochemical Journal, vol. 333, no. 2, pp. 247–251, 1998. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Suzuki, K. Ishii, H. Aizaki, and T. Wakita, “Hepatitis C viral life cycle,” Advanced Drug Delivery Reviews, vol. 59, no. 12, pp. 1200–1212, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. D. Moradpour, F. Penin, and C. M. Rice, “Replication of hepatitis C virus,” Nature Reviews Microbiology, vol. 5, no. 6, pp. 453–463, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Dubuisson and F.-L. Cosset, “Virology and cell biology of the hepatitis C virus life cycle—an update,” Journal of Hepatology, vol. 61, no. 1, supplement, pp. S3–S13, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. T. K. H. Scheel and C. M. Rice, “Understanding the hepatitis C virus life cycle paves the way for highly effective therapies,” Nature Medicine, vol. 19, no. 7, pp. 837–849, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. M. B. Zeisel, J. Lupberger, I. Fofana, and T. F. Baumert, “Host-targeting agents for prevention and treatment of chronic hepatitis C—perspectives and challenges,” Journal of Hepatology, vol. 58, no. 2, pp. 375–384, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. J. M. Baugh, J. A. Garcia-Rivera, and P. A. Gallay, “Host-targeting agents in the treatment of hepatitis C: a beginning and an end?” Antiviral Research, vol. 100, no. 2, pp. 555–561, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. J. G. O'Leary and G. L. Davis, “Hepatitis C virus replication and potential targets for direct-acting agents,” Therapeutic Advances in Gastroenterology, vol. 3, no. 1, pp. 43–53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. Q. Xue, H. Ding, M. Liu et al., “Inhibition of hepatitis C virus replication and expression by small interfering RNA targeting host cellular genes,” Archives of Virology, vol. 152, no. 5, pp. 955–962, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Zhang, O. Yamada, T. Sakamoto et al., “Down-regulation of viral replication by adenoviral-mediated expression of siRNA against cellular cofactors for hepatitis C virus,” Virology, vol. 320, no. 1, pp. 135–143, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. Waheed, A. Bhatti, and M. Ashraf, “RNA dependent RNA polymerase of HCV: a potential target for the development of antiviral drugs,” Infection, Genetics and Evolution, vol. 14, no. 1, pp. 247–257, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. L. Trejo-Ávila, R. Elizondo-González, K. D. C. Trujillo-Murillo, P. Zapata-Benavides, C. Rodríguez-Padilla, and A. M. Rivas-Estilla, “Antiviral therapy: inhibition of hepatitis C virus expression by RNA interference directed against the NS5B region of the viral genome,” Annals of Hepatology, vol. 6, no. 3, pp. 174–180, 2007. View at Google Scholar · View at Scopus
  62. U. Ali Ashfaq, M. Ansar, M. T. Sarwar, T. Javed, S. Rehman, and S. Riazuddin, “Post-transcriptional inhibition of hepatitis C virus replication through small interference RNA,” Virology Journal, vol. 8, no. 1, article 112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. B. Chang, C. H. Lee, J. H. Lee, and S.-W. Lee, “Comparative analysis of intracellular inhibition of hepatitis C virus replication by small interfering RNAs,” Biotechnology Letters, vol. 32, no. 9, pp. 1231–1237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Upadhyay, U. Dixit, D. Manvar, N. Chaturvedi, and V. N. Pandey, “Affinity capture and identification of host cell factors associated with hepatitis C virus (+) strand subgenomic RNA,” Molecular and Cellular Proteomics, vol. 12, no. 6, pp. 1539–1552, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. S.-C. Chan, S.-Y. Lo, J.-W. Liou et al., “Visualization of the structures of the hepatitis C virus replication complex,” Biochemical and Biophysical Research Communications, vol. 404, no. 1, pp. 574–578, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. D. Moradpour, M. J. Evans, R. Gosert et al., “Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes,” Journal of Virology, vol. 78, no. 14, pp. 7400–7409, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. E. Gottlieb and J. A. Steitz, “The RNA binding protein La influences both the accuracy and the efficiency of RNA polymerase III transcription in vitro,” EMBO Journal, vol. 8, no. 3, pp. 841–850, 1989. View at Google Scholar · View at Scopus
  68. S. Weser, M. Bachmann, K. H. Seifart, and W. Meibssner, “Transcription efficiency of human polymerase III genes in vitro does not depend on the RNP-forming autoantigen La,” Nucleic Acids Research, vol. 28, no. 20, pp. 3935–3942, 2000. View at Publisher · View at Google Scholar · View at Scopus
  69. J. P. Wyles and N. D. Ridgway, “VAMP-associated protein-A regulates partitioning of oxysterol-binding protein-related protein-9 between the endoplasmic reticulum and Golgi apparatus,” Experimental Cell Research, vol. 297, no. 2, pp. 533–547, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. J. P. Wyles, C. R. McMaster, and N. D. Ridgway, “Vesicle-associated membrane protein-associated protein-A (VAP-A) interacts with the oxysterol-binding protein to modify export from the endoplasmic reticulum,” Journal of Biological Chemistry, vol. 277, no. 33, pp. 29908–29918, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. Y. Jia, T. Song, C. Wei et al., “Negative regulation of MAVS-mediated innate immune response by PSMA7,” The Journal of Immunology, vol. 183, no. 7, pp. 4241–4248, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. R. Prabhu, R. F. Garry, and S. Dash, “Small interfering RNA targeted to stem-loop II of the 5′ untranslated region effectively inhibits expression of six HCV genotypes,” Virology Journal, vol. 3, article 100, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. T. Watanabe, M. Sudoh, M. Miyagishi et al., “Intracellular-diced dsRNA has enhanced efficacy for silencing HCV RNA and overcomes variation in the viral genotype,” Gene Therapy, vol. 13, no. 11, pp. 883–892, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. I. Fofana, F. Xiao, C. Thumann et al., “A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits hepatitis C virus cell-cell transmission,” PLoS ONE, vol. 8, no. 5, Article ID e64221, 2013. View at Publisher · View at Google Scholar · View at Scopus